Category: 502649-32-3

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.502649-32-3,1-Boc-3-Isopropylpiperazine,as a common compound, the synthetic route is as follows.

502649-32-3, A mixture of 10- hydroxy-10-((6-oxo-4-phenylpyrimidin-1 (6/-/)-yl)methyl)-7-azaspiro[4.5]decane-7-carbonyl chloride (10 mg, 0.0249 mmol), tert- butyl 3-isopropylpiperazine-1-carboxylate (8.5 mg, 0.0373 mmol) and DIPEA (13 mI_, 0.0746 mmol) in DCM (0.5 mL) was stirred at rt for 2 h 30 min before tert- butyl 3-isopropylpiperazine-1-carboxylate (8.5 mg, 0.0373 mmol) and DIPEA (13 pL, 0.0746 mmol) were added. The reaction was stirred for further 18 h 45 min before DMF (0.5 mL) was added and the reaction stirred for a further 6 days. The reaction mixture was diluted with saturated NaHC03(aq) (15 mL) and the resulting mixture was extracted with DCM (3 x 10 mL) using a phase separator. The combined organic phases were concentrated under reduced pressure and the residue was purified by flash (1504) chromatography (0-100% EtOAc in cyclohexane) to give the title compound (7.7 mg, 52%) as colourless glass. LCMS (Method A): RT = 1.70 min, m/z = 594 [M+H]+.

502649-32-3 1-Boc-3-Isopropylpiperazine 44558596, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; ALMAC DISCOVERY LIMITED; ROUNTREE, James Samuel Shane; WHITEHEAD, Steven Kristopher; TREDER, Adam Piotr; PROCTOR, Lauren Emma; SHEPHERD, Steven David; BURKAMP, Frank; COSTA, Joana Rita Castro; O’DOWD, Colin; HARRISON, Timonthy; (333 pag.)WO2019/150119; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.502649-32-3,1-Boc-3-Isopropylpiperazine,as a common compound, the synthetic route is as follows.

Exchanging 2,4-dichloropyrimidine for 2,4-dichloro-5-fluoropyrimidine and phenylboronic acid for 2-(4-(methoxymethyl)phenyl)-4,4,5,5-tetramethyl-l,3,2- dioxaborolane, the first step of Example 137 was used to prepare 2-chloro-5-fluoro-4-(4- (methoxymethyl)phenyl)pyrimidine. To a stirred solution of this intermediate (0.400 g, 1.58 mol) in toluene (8 mL) was added tert-butyl 3-isopropylpiperazine-l-carboxylate (0.434 g, 1.90 mmol), bis(tri-tert-butylphosphine)palladium(0) (0.081 g, 0.158 mmol), trimethylhexadecylammonium chloride (0.101 g, 0.316 mmol) and a 50% aqueous sodium hydroxide solution (0.25 mL, 4.73 mmol). The mixture was heated at 100 C overnight and concentrated. The residue was purified by flash chromatography over silica using a hexane/ethyl acetate eluant to afford partially purified tert-butyl 4-(5-fluoro-4-(4- (methoxymethyl)phenyl)pyrimidin-2-yl)-3 -isopropylpiperazine- 1 -carboxylate as light yellow oil (0.500 g). This material was taken up in dichloromethane (5 mL), stirred and treated with trifluoroacetic acid (3.0 mL). After 3 hours, the reaction was concentrated and the residue was purified by reversed-phase flash chromatography over CI 8 silica using a acetonitrile/water/trifluoroacetic acid eluant. 5-Fluoro-2-(2-isopropylpiperazin-l- yl)-4-(4-(methoxymethyl)phenyl)pyrimidine was afforded as a light yellow oil (0.200 g, 36% for two steps). Using General Procedure A and Intermediate 5, this intermediate was used to generate the title compound as a white solid (0.105 g, 63%). 1H NMR (500 MHz, CDCls) delta 8.24 (d, J = 3.5 Hz, 1H), 8.08 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 4.75-4.72 (m, 1H), 4.59-4.55 (m, 3H), 4.33-4.31 (m, 1H), 3.94-3.86 (m, 2H), 3.45 (s, 3H), 3.28-3.19 (m, 2H), 3.07-2.85 (m, 7H), 2.43-2.40 (m, 1H), 2.26-2.19 (m, 1H), 1.94-1.50 (m, 9H), 1.13 (t, J = 7.5 Hz, 3H), 0.87 (d, J = 7.5 Hz, 3H) ppm. 13C NMR (125 MHz, CDCI3) delta 158.4, 157.0, 151.1, 151.0, 150.4, 148.4, 146.7, 146.4, 140.9, 133.4, 129.0, 128.9, 127.5, 74.2, 59.0, 58.3, 57.5, 57.3, 53.2, 47.8, 47.6, 46.4, 46.1, 44.0, 43.9, 43.5, 43.3, 39.9, 39.7, 39.1, 36.7, 36.4, 27.1, 27.0, 25.9, 25.7, 24.4, 24.1, 20.4, 20.2, 19.1, 19.0 ppm. Purity: > 99% LCMS (214 nm & 254 nm); retention time 1.54 min; (M+H+) 525.3., 502649-32-3

As the paragraph descriping shows that 502649-32-3 is playing an increasingly important role.

Reference£º
Patent; GENZYME CORPORATION; BOURQUE, Elyse; CABRERA-SALAZAR, Mario, A.; CELATKA, Cassandra; CHENG, Seng, H.; HIRTH, Bradford; GOOD, Andrew; JANCSICS, Katherine; MARSHALL, John; METZ, Markus; SCHEULE, Ronald, K.; SKERLJ, Renato; XIANG, Yibin; ZHAO, Zhong; LEONARD, John; NATOLI, Thomas; MAKINO, Elina; HUSSON, Herve; BESKROVNAYA, Oxana; WO2014/43068; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

502649-32-3,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.502649-32-3,1-Boc-3-Isopropylpiperazine,as a common compound, the synthetic route is as follows.

To a solution of tert-butyl 3-isopropylpiperazine-1-carboxylate (830 mg, 3.6 mmol) and 2-chloroquinaxaline (600 mg, 3.6 mmol) in dimethyl sulfoxide (5 mL), cesium fluoride (550 mg, 3.6mmol) was added. The reaction mixture was stirred at 60 oc for 30 hours, and then the reactionmixture was poured into water (70 mL) and extracted with diethyl ether (2×20 mL). The crudeproduct was purified by silica gel column chromatography eluting with mixture hexane:ethyl acetate10 (4:1) to afford 600 mg, 46% of the titled compound as a light-yellow solid. 1H NMR (300 MHz,15DMSO-d6) o ppm 0.84-0.90 (m, 3H), 1.16-1.25 (m, 3H), 1.50 (s, 9H), 2.20-2.30 (m, 1H), 3.00-3.12(m, 2H), 3.20-3.28 (m, 1H), 4.17-4.23 (m, 1H), 4.30-4.36 (m, 1H), 4.55-4.65 (m, 1H), 7.55-7.62 (m,1H), 7.72-7.78 (m, 1H), 7.85-7.90 (m, 1H), 8.15-7.23 (m, 1H), 8.58 (s, 1H).

The synthetic route of 502649-32-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ABBVIE INC.; GOMTSIAN, Artour; DEKHTYAR, Tatyana; FRANK, Kristine E.; FRIEDMAN, Michael M.; JOSEPHSOHN, Nathan; MOLLA, M-Akhteruzz; VASUDEVAN, Anil; NG, Teresa; SHAFEEV, Mikhail; WO2014/5129; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics